DOCSLIB.ORG

Vasculopathy and Vasculitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vasculopathy and Vasculitis Danoushka Tememe, MD Vasculopathy and Vasculitis • Fibromuscular Dysplasia • Moyamoya • Snedden’s Syndrome Overview • Susac’s Syndrome • Systemic Vasculitis • Primary angiitis of the CNS Fibromuscular Dysplasia • FMD is a noninflammatory, nonatherosclerotic arterial disease of the medium-sized arteries throughout the body, which could lead to arterial stenosis, occlusion, aneurysm, and dissection. • The renal and carotid/vertebral arteries are most frequently affected • Iliac, mesenteric, subclavian arteries Fibromuscular Dysplasia • Often multifocal and bilateral. • Usually involves the mid segment of the vessels and spares origins • Age 25 to 50 years and affects women more often than men (3:1). Hypertension TIA/Stroke Spontaneous dissection Presentation Neck pain Pulsatile tinnitus Horner’s syndrome Vessel wall layers Typical string-of-beads pattern with alternating regions of lumen narrowing and vessel dilatation over a length of 3 – 5 cm FMD “String of beads” Extreme tortuosity “S curve” • There is no standard protocol to treat FMD • Aim of treatment is to improve blood flow and depends on which arteries are affected and the severity • Balloon angioplasty +/- stent Treatment • The carotid arteries should be imaged if FMD is found elsewhere in the body • Aspirin daily • Smoking cessation Moyamoya • Moyamoya disease is a progressive occlusive arteriopathy of the bilateral supraclinoid internal carotid arteries • Moyamoya syndrome: Down syndrome, neurofibromatosis type 1, sickle cell • Moyamoya-like vasculopathy: radiation, meningitis Moyamoya • Abnormal network of fine collateral vessels • Additional collaterals may develop: • Leptomeningeal collaterals from the posterior cerebral artery • Transdural collaterals from the external carotid artery • Can present with TIA/stroke (50-75%) or intracranial hemorrhage (IPH or SAH). • Seizures, headache • Fragile collaterals are prone to hemorrhage and Presentation hemodynamic failure. • Symptomatic episodes of ischemia may be triggered by exercise, crying, coughing, straining, fever, hyperventilation, dehydration, hypotension (e.g., general anesthesia for minor procedures). Smooth Muscle Proliferation and Intraluminal Thrombi Suzuki Grading System Moyamoya Stage 3/4 Stage 4/5 Ivy Sign: Sulcal flair hyperintensities representing slow flow from leptomeningeal collaterals Indicates decreased CVR Brush Sign Brush Sign on SWI Correlates with Severity of Moyamoya Steal Phenomenon • Administration of a vasodilator such as Diamox can assess cerebral reserve by observing cerebrovascular reactivity to hemodynamic stress. Post-op MRA showing STA-MCA bypass as high signal intensity SPECT seven days after left STA-MCA bypass demonstrating marked improvement in CBF Post- • Moyamoya vessels start regressing 1 month after bypass surgery. treatment changes • STA caliber increases 3 months after surgery. following STA- • ICAT steno-occlusion quickly progresses after MCA bypass surgery. Sneddon Syndrome • Progressive disorder affecting small- and medium-sized blood vessels. • Cerebral, ocular, renal, and cardiac involvement • Characterized by livedo racemosa (net-like patterns of Sneddon Syndrome discoloration on the skin) and neurological abnormalities. • More common in women • Onset of neuro symptoms in the 3rd to 4th decade • The livedo generally occurs up to 10 years earlier Livedo Racemosa • Persistent, erythematous or violaceous discoloration of the skin, in a broken, branched, discontinuous and irregular pattern. • Located on limbs (100%), trunk (84–89%), buttocks (68–74%), or the hands or feet (53–59%) • Results from persistent impairment of peripheral blood flow caused by occlusion of small or medium-sized arteries • Does not disappear with rewarming • vs livedo reticularis, which is caused by temporary vasoconstriction • Skin biopsy: occlusion without inflammation of the small to medium-sized arteries at the border between dermis and subcutis. • May reveal thrombosis of subcutaneous arterioles and compensatory capillary dilation with blood stagnation. • Can also see intimal endothelial proliferation and proliferation of medial smooth muscle cells Diagnosis • Blood tests: check for antiphospholipid antibodies (40-50% of patients are aPL+) and rule out other autoimmune conditions (including lupus) • CECR1 gene implicated given its role in producing adenosine deaminase 2, which is an enzyme that helps support the lining of blood vessel walls. Intra-capillary (thin arrow) and mural (thick arrow) Skin Biopsy widespread thrombosis Biopsy • Biopsy site should be in the center of the lesions, where the skin seems to be untouched. • Multiple biopsies increase the diagnostic yield. • The goal of a biopsy is to obtain samples of the medium vessel found in the deep reticular dermis and subcutaneous fat, which may require a wedge or large punch biopsy for increased yield. Cerebral Angiogram • Shows peripheral small-vessel and medium-vessel vasculopathy resulting in pruning of the distal cortical vessels and tortuous irregular distal collaterals. • No specific treatment for underlying condition • Antiplatelet therapy • Can use anticoagulants if +antiphospholipid antibodies Treatment • ACE inhibitors may reduce endothelial proliferation • Nifedipine may reduce skin symptoms • No effect on cerebrovascular complications • Smoking cessation and avoidance of estrogen oral contraceptives Susac’s Syndrome • Autoimmune disease characterized by retinal, cochlear, and brain microangiopathy • Clinical triad of subacute encephalopathy, Susac’s Syndrome branched retinal artery occlusion, and sensorineural hearing loss • More common in women • Age of onset between 20-50 years of age "snowball“ infarcts of the central fibers of the corpus callosum with relative preservation of the peripheral fibers Classic infarcts in the internal capsule with a “string of pearls” pattern Vasculitides • Characterized by inflammation and necrosis of the blood vessel wall • Primary CNS vasculitis vs systemic vasculitis with involvement of the CNS • Systemic vasculitis can be separated into 3 main groups based on if they affect predominantly large-sized vessels, medium-sized, or small-sized vessels • Large vessels including the aorta are affected in giant-cell arteritis Vasculitides • Medium-size arteries in classic polyarteritis nodosa • The small-vessel vasculitides are separated in those with antineutrophil cytoplasm antibodies (ANCA) and those without. • Primary angiitis of the central nervous system (PACNS) affect both medium- and small-sized vessels • Major symptoms of cerebral vasculitis are stroke, headache and encephalopathy Classification of primary vasculitides. Classification of primary vasculitides Vessel size Granulomatous Nongranulomatous Large Giant cell arteritis Takayasu arteritis Medium Polyarteritis nodosa Kawasaki disease Small (with ANCA) Granulomatosis with polyangiitis Microscopic polyarteritis Churg–Strauss syndrome Small (with immune complexes) Cryoglobulinemic vasculitis Behçet syndrome • Major symptoms of cerebral angiitis are stroke, headache, and encephalopathy. • Other symptoms include seizures, cranial nerve palsies, or myelopathies. • Elevated ESR/CRP is seen in systemic vasculitis • May include anemia, thrombocytosis, elevated liver Symptoms enzymes, and low complement • Complement consumption is seen in vasculitis with immune complexes. • In PACNS, serum findings usually are normal, but CSF studies reveal inflammatory findings (ie mild lymphomonocytic pleocytosis or protein elevation) - ESR/CRP - CBC w/ diff - CMP (Cr, LFTs) - Coags - SPEP/UPEP - CK Lab tests in - ACE - Cryoglobulins - TSH, thyroid antibodies, suspected - ANA, ds-DNA, RF, histone antibodies, complement (C3/4), SSA/B, ANCA, BCx - RPR, HIV, Hep B/C vasculitis - Urine examination (ie hematuria, protein, UPEP, utox) - CSF: cell count in tube 1 and 4, gram stain, CSF culture, VZV ab, CMV PCR, EBV PCR DSA Carotid doppler Imaging CTA MRA 18-FDG PET is very sensitive in revealing inflamed vessels Diagnostic criteria for the diagnosis of Primary Angiitis of the CNS 1 Acquired neurological deficit unexplained after complete evaluation 2 Diagnostic cerebral angiogram with narrowing of vessels, areas of dilation and/or beaded vessel appearance, displacement of vessels or vessel occlusions 3 No evidence of systemic vasculitis or any other condition that could mimic the angiogram findings • PACNS is more common in males (2:1) • Onset most often occurs after 40 years of age • ESR not helpful Primary Angiitis of the CNS • CSF inflammation is observed in ~90% of patients • Histological findings are characterized by infiltrations of the vascular walls with mononuclear cells including lymphocytes, macrophages, and histiocytes Temporal Arteritis Takayasu Arteritis Large vessel vasculitides Diagnostic criteria of temporal arteritis Three of the five diagnostic criteria 1 Age 50 years or more 2 New headache 3 Tenderness of the superficial temporal artery 4 Elevated sedimentation rate, at least 50 mm/h 5 Giant cell arteritis in a biopsy specimen from the temporal artery Criteria for the diagnosis of Takayasu’s arteritis Takayasu’s arteritis may be diagnosed when at least three of these six criteria are present (sensitivity of 90.5% and a specificity of 97.8%) 1 Age at disease onset <50 years 2 Claudication of extremities 3 Decreased brachial artery pulse 4 Blood pressure [systolic] difference > 10mmHg between arms 5 Bruit over subclavian arteries or abdominal aorta 6 Arteriographic narrowing or occlusion of the aorta, its primary branches or large arteries
Load more

Recommended publications
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Documentationand Coding Tips: Peripheral Vascular Disease
    Documentation and Coding: Peripheral Vascular Disease (PVD)/ Peripheral Arterial Disease (PAD) Created May 2020 At Healthfirst, we are committed to helping providers accurately document and code their patients’ health records. Proper ICD-10 coding can provide a comprehensive view of a patient’s overall health. This tip sheet offers guidance on how to submit a diagnosis code with greater specificity for Peripheral Vascular Disease (PVD)/Peripheral Arterial Disease (PAD). The risk factors for peripheral vascular disease are similar to those for coronary artery disease. The terms arteriosclerosis and atherosclerosis may be used interchangeably for coding and documentation purposes. When completing documentation and coding, you should keep in mind the following: Type of graft Laterality (left, right, or bilateral) and side(s) affected by the complicating condition Type of bypass Any educational information provided to the patient Location of vein or artery graft affected Treatment plan, orders, testing, prescriptions, and referrals Complications like claudication, ulceration, or chest pain Updated status of condition (stable, improved, and/or worsening) Graft, Bypass, Location, Complications, and Laterality Use the chart below to ensure that you are coding properly. Note that this is not an inclusive list of codes and that you are required to have six digits for your diagnosis code. The location and laterality will help determine the fifth and sixth digits for the codes. Type of Graft Location/Laterality Description of Graft ICD-10-CM Without
    [Show full text]
  • A Cross Sectional Study of Cutaneous Manifestations in 300 Patients of Diabetes Mellitus
    International Journal of Advances in Medicine Khuraiya S et al. Int J Adv Med. 2019 Feb;6(1):150-154 http://www.ijmedicine.com pISSN 2349-3925 | eISSN 2349-3933 DOI: http://dx.doi.org/10.18203/2349-3933.ijam20190122 Original Research Article A cross sectional study of cutaneous manifestations in 300 patients of diabetes mellitus Sandeep Khuraiya1*, Nancy Lal2, Naseerudin3, Vinod Jain3, Dilip Kachhawa3 1Department of Dermatology, 2Department of Radiation Oncology , Gandhi Medical College, Bhopal, Madhya Pradesh, India 3Department of Dermatology, Dr. SNMC, Jodhpur, Rajasthan, India Received: 13 December 2018 Accepted: 05 January 2019 *Correspondence: Dr. Sandeep Khuraiya, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Diabetes Mellitus (DM) is a worldwide problem and one of the most common endocrine disorder. The skin is affected by both the acute metabolic derangements and the chronic degenerative complications of diabetes. Methods: The present study was a one-year cross sectional study from January 2014 to December 2014. All confirmed cases of DM with cutaneous manifestations irrespective of age, sex, duration of illness and associated diseases, willing to participate in the study were included in the study. Routine haematological and urine investigations, FBS, RBS and HbA1c levels were carried out in all patients. Results: A total of 300 patients of diabetes mellitus with cutaneous manifestations were studied.
    [Show full text]
  • Control Study of Pregnancy Complications and Birth Outcomes
    Hypertension Research (2011) 34, 55–61 & 2011 The Japanese Society of Hypertension All rights reserved 0916-9636/11 $32.00 www.nature.com/hr ORIGINAL ARTICLE Hypotension in pregnant women: a population-based case–control study of pregnancy complications and birth outcomes Ferenc Ba´nhidy1,Na´ndor A´ cs1, Erzse´bet H Puho´ 2 and Andrew E Czeizel2 Hypotension is frequent in pregnant women; nevertheless, its association with pregnancy complications and birth outcomes has not been investigated. Thus, the aim of this study was to analyze the possible association of hypotension in pregnant women with pregnancy complications and with the risk for preterm birth, low birthweight and different congenital abnormalities (CAs) in the children of these mothers in the population-based data set of the Hungarian Case–Control Surveillance of CAs, 1980–1996. Prospectively and medically recorded hypotension was evaluated in 537 pregnant women who later had offspring with CAs (case group) and 1268 pregnant women with hypotension who later delivered newborn infants without CAs (control group); controls were matched to sex and birth week of cases (in the year when cases were born), in addition to residence of mothers. Over half of the pregnant women who had chronic hypotension were treated with pholedrine or ephedrine. Maternal hypotension is protective against preeclampsia; however, hypotensive pregnant women were at higher risk for severe nausea or vomiting, threatened abortion (hemorrhage in early pregnancy) and for anemia. There was no clinically important difference in the rate of preterm births and low birthweight newborns in pregnant women with or without hypotension. The comparison of the rate of maternal hypotension in cases with 23 different CAs and their matched controls did not show a higher risk for CAs (adjusted OR with 95% confidence intervals: 0.66, 0.49–0.84).
    [Show full text]
  • Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Peripheral Arterial Occlusive Disease
    The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 April 2002 CPMP/EWP/714/98 rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE DISCUSSION IN THE EFFICACY WORKING PARTY September 1999 – September 2000 TRANSMISSION TO CPMP November 2000 RELEASE FOR CONSULTATION November 2000 DEADLINE FOR COMMENTS May 2001 DISCUSSION IN THE EFFICACY WORKING PARTY November 2001 – February 2002 TRANSMISSION TO CPMP April 2002 ADOPTION BY CPMP April 2002 DATE FOR COMING INTO OPERATION October 2002 Note: This revised Note for guidance will replace the previous Note for guidance (CPMP/EWP/233/95) , adopted in November 1995. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 8613 E-mail: [email protected] http://www.emea.eu.int EMEA 2002 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged NOTE FOR GUIDANCE ON CLINICAL INVESTIGATIONS OF MEDICINAL PRODUCTS IN THE TREATMENT OF CHRONIC PERIPHERAL ARTERIAL OCCLUSIVE DISEASE TABLE OF CONTENTS 1. INTRODUCTION .................................................................................................... 4 2. GENERAL CONSIDERATIONS REGARDING PAOD TRIALS..................... 4 2.1 PAOD Classification and Epidemiological Background ...................................... 4 2.2 Clinical Trial Features ............................................................................................
    [Show full text]
  • IWGDF Guideline on Diagnosis, Prognosis and Management of Peripheral Artery Disease in Patients with a Foot Ulcer and Diabetes
    IWGDF Guideline on diagnosis, prognosis and management of peripheral artery disease in patients with a foot ulcer and diabetes Part of the 2019 IWGDF Guidelines on the Prevention and Management of Diabetic Foot Disease IWGDF Guidelines AUTHORS Robert J. Hinchlife1, Rachael O. Forsythe2, Jan Apelqvist3, Ed J. Boyko4, Robert Fitridge5, Joon Pio Hong6, Konstantinos Katsanos7, Joseph L. Mills8, Sigrid Nikol9, Jim Reekers10, Maarit Venermo11, R. Eugene Zierler12, Nicolaas C. Schaper13 on behalf of the International Working Group on the Diabetic Foot (IWGDF) INSTITUTIONS 1 Bristol Centre for Surgical Research, University of Bristol, Bristol, UK 2 British Heart Foundation / University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, UK 3 Department of Endocrinology, University Hospital of Malmö, Sweden 4 Seattle Epidemiologic Research and Information Centre-Department of Veterans Afairs Puget Sound Health Care System and the University of Washington, Seattle, Washington, USA 5 Vascular Surgery, The University of Adelaide, Adelaide, South Australia, Australia 6 Asan Medical Center University of Ulsan, Seoul, Korea 7 Patras University Hospital School of Medicine, Rion, Patras, Greece 8 SALSA (Southern Arizona Limb Salvage Alliance), University of Arizona Health Sciences Center, Tucson, Arizona, USA 9 Asklepios Klinik St. Georg, Hamburg, Germany 10 Department of Vascular Radiology, Amsterdam Medical Centre, The Netherlands 11 Helsinki University Hospital, University of Helsinki, Finland 12 Department of Surgery, University of Washington, Seattle, Washington, USA 13 Div. Endocrinology, MUMC+, CARIM and CAPHRI Institute, Maastricht, The Netherlands KEYWORDS diabetic foot; foot ulcer; guidelines; peripheral artery disease; surgery; diagnosis; prognosis; vascular disease www.iwgdfguidelines.org IWGDF PAD Guideline ABSTRACT The International Working Group on the Diabetic Foot (IWGDF) has published evidence-based guidelines on the prevention and management of diabetic foot disease since 1999.
    [Show full text]
  • Vasculitis: Pearls for Early Diagnosis and Treatment of Giant Cell Arteritis
    Vasculitis: Pearls for early diagnosis and treatment of Giant Cell Arteritis Mary Beth Humphrey, MD, PhD Professor of Medicine McEldowney Chair of Immunology [email protected] Office Phone: 405 271-8001 ext 35290 October 2019 Relevant Disclosure and Resolution Under Accreditation Council for Continuing Medical Education guidelines disclosure must be made regarding relevant financial relationships with commercial interests within the last 12 months. Mary Beth Humphrey I have no relevant financial relationships or affiliations with commercial interests to disclose. Experimental or Off-Label Drug/Therapy/Device Disclosure I will be discussing experimental or off-label drugs, therapies and/or devices that have not been approved by the FDA. Objectives • To recognize early signs of vasculitis. • To discuss Tocilizumab (IL-6 inhibitor) as a new treatment option for temporal arteritis. • To recognize complications of vasculitis and therapies. Professional Practice Gap Gap 1: Application of imaging recommendations in large vessel vasculitis Gap 2: Application of tocilizimab in treatment of giant cell vasculitis Cranial Symptoms Aortic Vision loss Aneurysm GCA Arm PMR Claudication FUO Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Giant Cell Arteritis • Most common form of systemic vasculitis in adults – Incidence: ~ 1/5,000 persons > 50 yrs/year – Lifetime risk: 1.0% (F) 0.5% (M) • Cause: unknown At risk: Women (80%) > men (20%) Northern European ancestry>>>AA>Hispanics Age: average age at onset ~73 years Smoking: 6x increased risk Kermani TA, et al Ann Rheum Dis.
    [Show full text]
  • Jordan M. Garrison, Md Facs Fasmbs What Are We Talking About?
    PERIPHERAL VASCULAR DISEASE JORDAN M. GARRISON, MD FACS FASMBS WHAT ARE WE TALKING ABOUT? Peripheral Arterial Disease (PAD) • Near or Complete obstruction of > 1 Peripheral Artery Peripheral Venous Reflux Disease • Varicose Veins • Chronic Venous Stasis Ulcer Disease • Phlegmasia Cerulia Dolans or Alba Dolans (Milk Leg) • Deep Vein Thrombosis and Pulmonary Embolus Disease Coronary Artery Disease ◦ Myocardial Infarct Aneurysmal Disease • Aortic • Popliteal Cerebral and Carotid Artery Disease • Stroke • TIA Renal Vascular Hypertensive Disease • High Blood Pressure • Kidney Failure Peripheral Arterial Disease PREVELANCE Males > Females 10% of People over 60 Race • AA double the rate of all other ethnicities High Income Countries Peripheral Arterial Disease RISK FACTORS Smoking is the #1 risk factor Diabetes Mellitus Diet Obesity ETOH Cholesterol Heredity Lifestyle Homocysteine, C Reactive Protein, Fibrinogen Arterial Anatomy Lower Extremity Anatomy Plaque Formation Plaque Peripheral Arterial Disease Claudication • Disabling • Intestinal Limb Threatening Ischemia(LTI) Critical Limb Ischemia(CLI) • Rest Pain • Tissue Loss • Gangrene Disabling Claudication Intestinal Ischemia Intestinal Claudication Peripheral Arterial Disease Claudication • Disabling • Intestinal Limb Threatening Ischemia(LTI) Critical Limb Ischemia(CLI) • Rest Pain • Tissue Loss • Gangrene Rest Pain/ Dependent Rubor Tissue Loss Gangrene Peripheral Artery Disease Diagnosis Segmental Pressures • Lower extremity Blood Pressures ABI • Nl >1.0, Diabetes will give elevated reading
    [Show full text]
  • Definitions • Septic Shock
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis Definitions • Septic shock: Persisting hypotension despite volume resuscitation, requiring vasopressors to maintain mean artery pressure (MAP) ≥65 mmHg and serum lactate level >2 mmol/L (1). • Renal failure: Doubling of basal Creatinine value or urine output <0.5 ml/kg/h for ≥12h (2) • Heart failure: Gradual or rapid change in heart failure signs and symptoms resulting in a need for urgent therapy (3). • Myocarditis: Myocarditis was diagnosed if serum levels of high-sensitivity cardiac troponin I were above the 99th percentile upper reference limit and compatible abnormalities were shown in electrocardiography and echocardiography. • Encephalopathy: Impaired consciousness as change of consciousness level (somnolence, stupor, and coma) or consciousness content (confusion and delirium) (4). • Thrombosis: Clinically or by imaging diagnosed acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism (5). References 1. World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection- when-novel-coronavirus-(ncov)-infection-is-suspected. 2. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179-84. 10.1159/000339789. 3. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958-3968. 4. Mao L, Jin H, Wang M, et al.
    [Show full text]
  • Relapsing Polychondritis
    Relapsing polychondritis Author: Professor Alexandros A. Drosos1 Creation Date: November 2001 Update: October 2004 Scientific Editor: Professor Haralampos M. Moutsopoulos 1Department of Internal Medicine, Section of Rheumatology, Medical School, University of Ioannina, 451 10 Ioannina, GREECE. [email protected] Abstract Keywords Disease name and synonyms Diagnostic criteria / Definition Differential diagnosis Prevalence Laboratory findings Prognosis Management Etiology Genetic findings Diagnostic methods Genetic counseling Unresolved questions References Abstract Relapsing polychondritis (RP) is a multisystem inflammatory disease of unknown etiology affecting the cartilage. It is characterized by recurrent episodes of inflammation affecting the cartilaginous structures, resulting in tissue damage and tissue destruction. All types of cartilage may be involved. Chondritis of auricular, nasal, tracheal cartilage predominates in this disease, suggesting response to tissue-specific antigens such as collagen II and cartilage matrix protein (matrillin-1). The patients present with a wide spectrum of clinical symptoms and signs that often raise major diagnostic dilemmas. In about one third of patients, RP is associated with vasculitis and autoimmune rheumatic diseases. The most commonly reported types of vasculitis range from isolated cutaneous leucocytoclastic vasculitis to systemic polyangiitis. Vessels of all sizes may be affected and large-vessel vasculitis is a well-recognized and potentially fatal complication. The second most commonly associated disorder is autoimmune rheumatic diseases mainly rheumatoid arthritis and systemic lupus erythematosus . Other disorders associated with RP are hematological malignant diseases, gastrointestinal disorders, endocrine diseases and others. Relapsing polychondritis is generally a progressive disease. The majority of the patients experience intermittent or fluctuant inflammatory manifestations. In Rochester (Minnesota), the estimated annual incidence rate was 3.5/million.
    [Show full text]
  • Coronary Microvascular Dysfunction
    Journal of Clinical Medicine Review Coronary Microvascular Dysfunction Federico Vancheri 1,*, Giovanni Longo 2, Sergio Vancheri 3 and Michael Henein 4,5,6 1 Department of Internal Medicine, S.Elia Hospital, 93100 Caltanissetta, Italy 2 Cardiovascular and Interventional Department, S.Elia Hospital, 93100 Caltanissetta, Italy; [email protected] 3 Radiology Department, I.R.C.C.S. Policlinico San Matteo, 27100 Pavia, Italy; [email protected] 4 Institute of Public Health and Clinical Medicine, Umea University, SE-90187 Umea, Sweden; [email protected] 5 Department of Fluid Mechanics, Brunel University, Middlesex, London UB8 3PH, UK 6 Molecular and Nuclear Research Institute, St George’s University, London SW17 0RE, UK * Correspondence: [email protected] Received: 10 August 2020; Accepted: 2 September 2020; Published: 6 September 2020 Abstract: Many patients with chest pain undergoing coronary angiography do not show significant obstructive coronary lesions. A substantial proportion of these patients have abnormalities in the function and structure of coronary microcirculation due to endothelial and smooth muscle cell dysfunction. The coronary microcirculation has a fundamental role in the regulation of coronary blood flow in response to cardiac oxygen requirements. Impairment of this mechanism, defined as coronary microvascular dysfunction (CMD), carries an increased risk of adverse cardiovascular clinical outcomes. Coronary endothelial dysfunction accounts for approximately two-thirds of clinical conditions presenting with symptoms and signs of myocardial ischemia without obstructive coronary disease, termed “ischemia with non-obstructive coronary artery disease” (INOCA) and for a small proportion of “myocardial infarction with non-obstructive coronary artery disease” (MINOCA). More frequently, the clinical presentation of INOCA is microvascular angina due to CMD, while some patients present vasospastic angina due to epicardial spasm, and mixed epicardial and microvascular forms.
    [Show full text]
  • Guideline-Management-Giant-Cell
    Arthritis Care & Research Vol. 73, No. 8, August 2021, pp 1071–1087 DOI 10.1002/acr.24632 © 2021 American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis Mehrdad Maz,1 Sharon A. Chung,2 Andy Abril,3 Carol A. Langford,4 Mark Gorelik,5 Gordon Guyatt,6 Amy M. Archer,7 Doyt L. Conn,8 Kathy A. Full,9 Peter C. Grayson,10 Maria F. Ibarra,11 Lisa F. Imundo,5 Susan Kim,2 Peter A. Merkel,12 Rennie L. Rhee,12 Philip Seo,13 John H. Stone,14 Sangeeta Sule,15 Robert P. Sundel,16 Omar I. Vitobaldi,17 Ann Warner,18 Kevin Byram,19 Anisha B. Dua,7 Nedaa Husainat,20 Karen E. James,21 Mohamad A. Kalot,22 Yih Chang Lin,23 Jason M. Springer,1 Marat Turgunbaev,24 Alexandra Villa-Forte, 4 Amy S. Turner,24 and Reem A. Mustafa25 Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particu- lar patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome.
    [Show full text]